Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Idelalisib

FDA-approved product (tablet, oral), marketed as Idelalisib, Zydelig.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Idelalisib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Neoplasm
  • Neoplasm of mature B-cells
  • Non-Hodgkins lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phosphatidylinositol-3-kinase (pi3k) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Idelalisib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Idelalisib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

    NCT02436135 · start 2015-06-05

    Registered record
    Registry ID
    NCT02436135
    Conditions
    Myelofibrosis
    Interventions
    Idelalisib; Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2015-06-05
    Completion
    2017-11-20
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelofibrosis
    InterventionIdelalisib; Ruxolitinib
    PhasePhase 1
    Registry statusTerminated

  • Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

    NCT02445131 · start 2015-05-28

    Registered record
    Registry ID
    NCT02445131
    Conditions
    Chronic Lymphocytic Leucemia
    Interventions
    Bendamustine; GA101; CAL-101
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-05-28
    Completion
    2022-03-09
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leucemia
    InterventionBendamustine; GA101; CAL-101
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

    NCT01980875 · start 2015-04-21

    Registered record
    Registry ID
    NCT01980875
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Idelalisib; Chlorambucil; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-04-21
    Completion
    2016-05-13
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionIdelalisib; Chlorambucil; Obinutuzumab
    PhasePhase 3
    Registry statusTerminated

  • Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

    NCT02332980 · start 2015-02-19

    Registered record
    Registry ID
    NCT02332980
    Conditions
    Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Splenic Marginal Zone Lymphoma; Recurrent Waldenstrom Macroglobulinemia; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Refractory Follicular Lymphoma; Refractory Lymphoplasmacytic Lymphoma; Refractory Nodal Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Splenic Marginal Zone Lymphoma; Refractory Waldenstrom Macroglobulinemia; Richter Syndrome; Waldenstrom Macroglobulinemia
    Interventions
    Ibrutinib; Idelalisib; Laboratory Biomarker Analysis; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-02-19
    Completion
    2022-01-04
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Recurrent Grade 1 Follicular Lymphoma +19 more
    InterventionIbrutinib; Idelalisib; Laboratory Biomarker Analysis; Pembrolizumab
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

    NCT02242045 · start 2014-10-01

    Registered record
    Registry ID
    NCT02242045
    Conditions
    Chronic Lymphocytic Leukemia; Indolent Non-Hodgkin Lymphoma; Follicular Lymphoma; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia); Marginal Zone Lymphoma
    Interventions
    Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-10-01
    Completion
    2017-10-17
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Indolent Non-Hodgkin Lymphoma; Follicular Lymphoma; Small Lymphocytic Lymphoma +2 more
    InterventionIdelalisib
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

    NCT02044822 · start 2014-08-06

    Registered record
    Registry ID
    NCT02044822
    Conditions
    B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
    Interventions
    Idelalisib; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-08-06
    Completion
    2016-05-17
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
    InterventionIdelalisib; Rituximab
    PhasePhase 2
    Registry statusTerminated

  • A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

    NCT02135133 · start 2014-06

    Registered record
    Registry ID
    NCT02135133
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Idelalisib; Ofatumumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-06
    Completion
    2020-10-06
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionIdelalisib; Ofatumumab
    PhasePhase 2
    Registry statusCompleted

  • Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

    NCT01838434 · start 2013-10-17

    Registered record
    Registry ID
    NCT01838434
    Conditions
    Relapsed/Refractory Mantle Cell Lymphoma
    Interventions
    lenalidomide; idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10-17
    Completion
    2017-05-01
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed/Refractory Mantle Cell Lymphoma
    Interventionlenalidomide; idelalisib
    PhasePhase 1
    Registry statusCompleted

  • Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

    NCT01644799 · start 2013-08-02

    Registered record
    Registry ID
    NCT01644799
    Conditions
    Recurrent Follicular Lymphoma
    Interventions
    idelalisib; lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08-02
    Completion
    2017-05
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Follicular Lymphoma
    Interventionidelalisib; lenalidomide
    PhasePhase 1
    Registry statusCompleted

  • Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

    NCT01796470 · start 2013-06-20

    Registered record
    Registry ID
    NCT01796470
    Conditions
    Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Diffuse Large B-cell Lymphoma; Indolent Non-Hodgkin's Lymphoma
    Interventions
    Entospletinib; Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-06-20
    Completion
    2016-12-22
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Diffuse Large B-cell Lymphoma; Indolent Non-Hodgkin's Lymphoma
    InterventionEntospletinib; Idelalisib
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

    NCT01732913 · start 2013-01-16

    Registered record
    Registry ID
    NCT01732913
    Conditions
    Indolent Non-Hodgkin's Lymphomas
    Interventions
    Placebo; Rituximab; Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-01-16
    Completion
    2016-05-18
    Enrolment
    295

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIndolent Non-Hodgkin's Lymphomas
    InterventionPlacebo; Rituximab; Idelalisib
    PhasePhase 3
    Registry statusTerminated

  • Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

    NCT01732926 · start 2013-01-02

    Registered record
    Registry ID
    NCT01732926
    Conditions
    Indolent Non-Hodgkin's Lymphomas
    Interventions
    Idelalisib; Rituximab; Bendamustine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-01-02
    Completion
    2016-05-17
    Enrolment
    475

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIndolent Non-Hodgkin's Lymphomas
    InterventionIdelalisib; Rituximab; Bendamustine; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

    NCT01659021 · start 2012-12-04

    Registered record
    Registry ID
    NCT01659021
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Idelalisib; Ofatumumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-12-04
    Completion
    2018-08-15
    Enrolment
    261

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionIdelalisib; Ofatumumab
    PhasePhase 3
    Registry statusTerminated

  • Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

    NCT01539291 · start 2012-10-03

    Registered record
    Registry ID
    NCT01539291
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-10-03
    Completion
    2018-06-29
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionIdelalisib
    PhasePhase 3
    Registry statusTerminated

  • Phase 1b Safety and Efficacy Study of TRU-016

    NCT01644253 · start 2012-09

    Registered record
    Registry ID
    NCT01644253
    Conditions
    Chronic Lymphocytic Leukemia; Peripheral T-cell Lymphoma
    Interventions
    20 mg/kg TRU-016 + Rituximab; 10 mg/kg TRU-016 + Rituximab; TRU-016 20 mg/kg + Obinutuzumab; TRU-016 6-20 mg/kg + idelalisib + rituximab; TRU-016 10-20 mg/kg + ibrutinib; TRU-016 10-20 mg/kg + bendamustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-09
    Completion
    2021-04-21
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Peripheral T-cell Lymphoma
    Intervention20 mg/kg TRU-016 + Rituximab; 10 mg/kg TRU-016 + Rituximab; TRU-016 20 mg/kg + Obinutuzumab; TRU-016 6-20 mg/kg + idelalisib + rituximab +2 more
    PhasePhase 1
    Registry statusTerminated